Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference

LONDON and RALEIGH, N.C. - Verona Pharma plc (Nasdaq: VRNA) ('Verona Pharma'), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference. The presentation will be available on-demand starting at 7:00 AM EST / 12:00 PM GMT on Monday, January 10, 2022.

A webcast of the event will be available for 90 days on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com.

Contact:

Verona Pharma plc

US

Tel: [phone]

UK

Tel: [phone]

Victoria Stewart

Director

Investor Relations and Communications

E: [e-mail]

Argot Partners

US Investor

Tel: [phone]

E: [e-mail]

Kimberly Minarovich

Michael Barron

Optimum Strategic Communications

Tel: [phone]

[e-mail]

International Media and European Investor

Mary Clark

Stella Lempidaki

Zoe Bolt

About Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma's product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE ('Ensifentrine as a Novel inHAled Nebulized COPD thErapy') for COPD maintenance treatment. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler ('DPI') and pressurized metered-dose inhaler ('pMDI'). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases.

(C) 2022 Electronic News Publishing, source ENP Newswire